CY1124364T1 - Μεθοδοι για την ανιχνευση aav - Google Patents

Μεθοδοι για την ανιχνευση aav

Info

Publication number
CY1124364T1
CY1124364T1 CY20211100262T CY211100262T CY1124364T1 CY 1124364 T1 CY1124364 T1 CY 1124364T1 CY 20211100262 T CY20211100262 T CY 20211100262T CY 211100262 T CY211100262 T CY 211100262T CY 1124364 T1 CY1124364 T1 CY 1124364T1
Authority
CY
Cyprus
Prior art keywords
aav
methods
detection
determining
particles
Prior art date
Application number
CY20211100262T
Other languages
Greek (el)
English (en)
Inventor
Xiaoying Jin
Catherine R. O'riordan
Lin Liu
Kate ZHANG
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59762045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1124364(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of CY1124364T1 publication Critical patent/CY1124364T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N30/06—Preparation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20211100262T 2016-08-15 2021-03-24 Μεθοδοι για την ανιχνευση aav CY1124364T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662375314P 2016-08-15 2016-08-15
PCT/US2017/046814 WO2018035059A1 (en) 2016-08-15 2017-08-14 Methods for detecting aav

Publications (1)

Publication Number Publication Date
CY1124364T1 true CY1124364T1 (el) 2022-07-22

Family

ID=59762045

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100262T CY1124364T1 (el) 2016-08-15 2021-03-24 Μεθοδοι για την ανιχνευση aav

Country Status (22)

Country Link
US (5) US11698377B2 (enExample)
EP (2) EP3851449A1 (enExample)
JP (3) JP7021191B2 (enExample)
KR (5) KR102922101B1 (enExample)
CN (2) CN118688363A (enExample)
AU (2) AU2017312951B2 (enExample)
CA (1) CA3033856A1 (enExample)
CL (2) CL2019000392A1 (enExample)
CR (1) CR20190127A (enExample)
CY (1) CY1124364T1 (enExample)
DK (1) DK3497207T3 (enExample)
ES (1) ES2863674T3 (enExample)
HU (1) HUE053747T2 (enExample)
IL (3) IL264819B2 (enExample)
MA (1) MA55748A (enExample)
MX (2) MX2019001938A (enExample)
PH (1) PH12019500316A1 (enExample)
SG (2) SG10201913002QA (enExample)
TN (1) TN2019000047A1 (enExample)
TW (2) TW202309068A (enExample)
WO (1) WO2018035059A1 (enExample)
ZA (2) ZA201900945B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
HUE053747T2 (hu) 2016-08-15 2021-07-28 Genzyme Corp Eljárások AAV kimutatására
RS65241B1 (sr) * 2017-02-28 2024-03-29 Univ Pennsylvania Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
EP3768695A4 (en) * 2018-02-27 2022-04-06 The Trustees of the University of Pennsylvania NOVEL ADENO-ASSOCIATED VIRUS (AAV) VECTORS, AAV VECTORS WITH REDUCED CAPSIID DEAMIDATION AND USES THEREOF
IL276859B2 (en) * 2018-02-27 2025-12-01 Univ Pennsylvania Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
EP3762500A1 (en) * 2018-03-06 2021-01-13 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
US11391707B2 (en) * 2018-07-27 2022-07-19 Waters Technologies Corporation Liquid chromatography/mass spectrometry methods for the analysis of polar molecules
US12195745B2 (en) * 2018-08-21 2025-01-14 Massachusetts Eye And Ear Infirmary Compositions and methods for modulating transduction efficiency of adeno-associated viruses
WO2020086893A1 (en) 2018-10-25 2020-04-30 Regeneron Pharmaceuticals, Inc. Methods for analysis of viral capsid protein composition
ES2965341T3 (es) * 2019-04-11 2024-04-12 Regenxbio Inc Métodos de cromatografía de exclusión por tamaño para la caracterización de composiciones de virus adenoasociados recombinantes
US11841352B2 (en) * 2019-07-31 2023-12-12 Thermo Finnigan Llc Determination and correction of retention time and mass/charge shifts in LC-MS experiments
EP4085255A1 (en) * 2020-01-03 2022-11-09 Sarepta Therapeutics, Inc. Methods for analyzing aav capsid proteins
WO2021155137A1 (en) 2020-01-29 2021-08-05 Genzyme Corporation Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof
CN111517359B (zh) * 2020-04-23 2021-08-20 江南大学 一种手性硫化铜超粒子的合成方法
RU2748540C1 (ru) * 2021-02-08 2021-05-26 Автономная некоммерческая образовательная организация высшего образования "Сколковский институт науки и технологий" Способ детектирования вируса SARS-CoV-2 методом масс-спектрометрии
US20220268783A1 (en) * 2021-02-19 2022-08-25 Waters Technologies Corporation Methods for peptide mapping of adeno-associated virus (aav) proteins
WO2022224965A1 (ja) * 2021-04-20 2022-10-27 株式会社ユニバーサル・バイオサンプリング 検体保持カード及びそれを用いた検体の検査方法
JP2024525686A (ja) * 2021-07-12 2024-07-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ａａｖカプシド比を決定するための液体クロマトグラフィーアッセイ
CA3225360A1 (en) * 2021-07-12 2023-01-19 Victoria COTHAM Online native mass spectrometry methods for assaying viral particles
CN113552349B (zh) * 2021-07-30 2022-07-19 上海勉亦生物科技有限公司 Aav蛋白外壳的检测方法
EP4462114A4 (en) * 2022-01-06 2025-04-16 FUJIFILM Corporation Method and kit for identifying sugar-bound amino acid site in protein
US20250110119A1 (en) * 2023-03-03 2025-04-03 Sartorius Bioanalytical Instruments, Inc. Methods for quantitating viral capsids
WO2024263520A1 (en) * 2023-06-19 2024-12-26 Regeneron Pharmaceuticals, Inc. Host cell protein analysis for adeno-associated virus (aav)-based gene therapy
AU2024378556A1 (en) * 2023-11-08 2026-05-21 Oxford Biomedica (Us) Llc Deamidation depleted adeno-associated virus product

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540931A (en) 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US6204059B1 (en) * 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
CA2264482A1 (en) 1996-09-06 1998-03-12 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6596535B1 (en) 1999-08-09 2003-07-22 Targeted Genetics Corporation Metabolically activated recombinant viral vectors and methods for the preparation and use
US7465583B2 (en) 2000-06-01 2008-12-16 The University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
SI1496944T1 (sl) 2002-05-01 2009-02-28 Univ Florida Izboljšani sistemi ekspresije RAAV za genetsko modifikacijo specifičnih kapsidnih proteinov
WO2004049385A2 (en) 2002-11-22 2004-06-10 Caprion Pharmaceuticals, Inc. Constellation mapping and uses thereof
US7510872B2 (en) 2003-02-26 2009-03-31 Nationwide Children's Hospital Recombinant adeno-associated virus production
JP4559429B2 (ja) 2003-05-21 2010-10-06 ジェンザイム・コーポレーション 空キャプシドを実質的に含まない組換えａａｖビリオン調製物を生成するための方法
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
US9441244B2 (en) * 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
PT3272872T (pt) 2005-10-20 2020-06-26 Uniqure Ip Bv Vetores aav melhorados produzidos em células de insetos
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
EP2342567A1 (en) 2008-09-19 2011-07-13 Charité Universitätsmedizin Berlin Identification and characterisation of recombinant viral gene therapy vectors
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
JP5956331B2 (ja) 2009-06-16 2016-07-27 ジェンザイム・コーポレーション 組換えａａｖベクターの改良された精製方法
DK2561073T3 (en) 2010-04-23 2016-12-12 Univ Massachusetts Aav vectors targeted to central nervous system and methods of use thereof
US20130217789A1 (en) * 2010-09-03 2013-08-22 North Carolina Central University Biodegradable liquogel and ph sensitive nanocarriers
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
CN103502458B (zh) 2011-02-17 2016-11-16 宾夕法尼亚大学托管会 用于改变组织特异性和改善aav9-介导的基因转移的组合物和方法
EP3795581A3 (en) 2011-08-24 2021-06-09 The Board of Trustees of the Leland Stanford Junior University New avv capsid proteins for nucleic acid transfer
JP6342886B2 (ja) * 2012-04-18 2018-06-13 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ Ａａｖカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法
US20140017716A1 (en) * 2012-07-11 2014-01-16 Siscapa Assay Technologies, Inc. Proteolytic digestion kit with dried reagents
GB201401707D0 (en) 2014-01-31 2014-03-19 Sec Dep For Health The Adeno-associated viral vectors
WO2015137802A1 (en) * 2014-03-10 2015-09-17 Uniqure Ip B.V. Further improved aav vectors produced in insect cells
HUE053747T2 (hu) 2016-08-15 2021-07-28 Genzyme Corp Eljárások AAV kimutatására

Also Published As

Publication number Publication date
US20250138024A1 (en) 2025-05-01
JP2024023460A (ja) 2024-02-21
AU2017312951B2 (en) 2024-02-08
ES2863674T3 (es) 2021-10-11
CL2019000392A1 (es) 2019-05-10
JP2019533803A (ja) 2019-11-21
EP3497207A1 (en) 2019-06-19
US12298313B1 (en) 2025-05-13
US20250027951A1 (en) 2025-01-23
EP3851449A1 (en) 2021-07-21
US11698377B2 (en) 2023-07-11
CN118688363A (zh) 2024-09-24
KR20230078834A (ko) 2023-06-02
KR102425289B1 (ko) 2022-07-27
KR20220107327A (ko) 2022-08-02
AU2017312951A1 (en) 2019-04-04
RU2019107207A3 (enExample) 2021-04-29
US20240044910A1 (en) 2024-02-08
EP3497207B1 (en) 2021-01-06
CN110168080A (zh) 2019-08-23
IL264819B2 (en) 2024-10-01
IL264819A (enExample) 2019-04-30
NZ791263A (en) 2025-11-28
IL312792B2 (en) 2026-03-01
NZ791267A (en) 2025-11-28
MX2023009081A (es) 2023-08-08
TWI781953B (zh) 2022-11-01
ZA202101002B (en) 2024-07-31
AU2024200349B2 (en) 2026-05-14
TN2019000047A1 (en) 2020-07-15
JP2022064980A (ja) 2022-04-26
JP7021191B2 (ja) 2022-02-16
TW202309068A (zh) 2023-03-01
AU2024200349A1 (en) 2024-02-08
BR112019002934A2 (pt) 2019-05-14
IL264819B1 (en) 2024-06-01
KR102538037B1 (ko) 2023-05-30
ZA201900945B (en) 2021-06-30
TW201825898A (zh) 2018-07-16
SG10201913002QA (en) 2020-03-30
US20250147042A1 (en) 2025-05-08
RU2019107207A (ru) 2020-09-15
KR20190039253A (ko) 2019-04-10
MX2019001938A (es) 2019-07-04
CN110168080B (zh) 2024-05-31
SG11201901221YA (en) 2019-03-28
PH12019500316A1 (en) 2019-08-05
IL312792B1 (en) 2025-11-01
WO2018035059A1 (en) 2018-02-22
WO2018035059A9 (en) 2019-03-14
NZ751711A (en) 2025-11-28
CL2019002912A1 (es) 2020-03-06
DK3497207T3 (da) 2021-03-22
KR20260036296A (ko) 2026-03-16
US20210041451A1 (en) 2021-02-11
IL323969A (en) 2025-12-01
IL312792A (en) 2024-07-01
CA3033856A1 (en) 2018-02-22
CR20190127A (es) 2019-06-25
HUE053747T2 (hu) 2021-07-28
KR102738219B1 (ko) 2024-12-05
US12123880B2 (en) 2024-10-22
KR102922101B1 (ko) 2026-02-03
MA55748A (fr) 2022-03-02
KR20240172773A (ko) 2024-12-10

Similar Documents

Publication Publication Date Title
ZA202101002B (en) Methods for detecting aav
CY1124118T1 (el) Αντισωματα προσδεσης θυμικης στρωματικης λεμφοποιητινης (tslp) και μεθοδοι χρησης των αντισωματων
EP4659816A3 (en) MODIFIED CAPSID PROTEINS FOR IMPROVED PARVOVIRUS VECTOR DELIVERY
CY1124182T1 (el) Αντισωματα anti-tmprss2 και θραυσματα δεσμευσης αντιγονου
CY1122520T1 (el) Συνθεσεις irna ιου ηπατιτιδας β (hbv) και μεθοδοι χρησης εξ αυτων
CY1122833T1 (el) Ογκολυτικος αδενοϊος που κωδικοποιει μια πρωτεϊνη β7
CY1125888T1 (el) Χημικες ενωσεις
CY1120489T1 (el) Εμβολια για hsv-2
MX2019000882A (es) Metodos de alta recuperacion escalables para una alta produccion de vector viral adenoasociado recombinante (raav) y vectores virales adenoasociados recombinantes (raav) producidos de este modo.
CY1125387T1 (el) Αντιγονα, διαβιβαστες, συνθεσεις του ιου της ανθρωπινης ανοσοανεπαρκειας, και μεθοδοι χρησης τους
WO2017066764A3 (en) Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
EA201791630A1 (ru) Аналитическое ультрацентрифугирование для определения характеристик рекомбинантных вирусных частиц
IL292625A (en) Viruses with modified capsid proteins
MX2022003681A (es) Caracterizacion de particulas virales de terapia genetica a traves del uso de cromatografia de exclusion de tama?os y las tecnologias de dispersion de la luz en multiples angulos.
EP3575398A4 (en) ADENO-ASSOCIATED VIRUS (AAV) CAPSIDE PROTEIN MUTANT
BR112019010565A2 (pt) aplicação viral de neoantígenos
MX383506B (es) Parvovirus porcino.
EP3347460A4 (en) MODIFIED ONCOLYTIC VACCINIA VIRUSES WITH CYTOKIN AND CAR-BOXY-REFERENCE EXPRESSION AND METHOD OF USE THEREOF
SG11201810014UA (en) Viral particle for rna transfer, especially into cells involved in immune response
CY1124707T1 (el) Συνθεσεις και μεθοδοι για την επαγωγη ενισχυμενης ανοσοαποκρισης με χρηση φορεων ιων poxvirus (ευλογοϊων)
SG11201810015YA (en) Particle for the encapsidation of a genome engineering system
MX378905B (es) Pestivirus.
EA202191137A1 (ru) Способы анализа композиции вирусного капсидного белка
DK3387132T3 (da) Aptamerer, nukleinsyremolekyler, polynukleotider, syntetiske antistofsammensætninger til påvisning af prrs-vira og behandling af prrs-virusinfektion
MY179251A (en) Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development